Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELETRIPTAN HYDROBROMIDE vs PATADAY ONCE DAILY RELIEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.
Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.
Acute treatment of migraine with or without aura in adults
Treatment of ocular itching associated with allergic conjunctivitis (FDA-approved)
40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.
1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).
Terminal elimination half-life is approximately 4-5 hours in healthy adults. In patients with hepatic impairment, half-life may be prolonged up to 8 hours. The half-life supports a clinical duration suitable for acute migraine treatment, with no accumulation with single doses.
Terminal elimination half-life is approximately 9 hours; allows twice-daily dosing for sustained symptom control.
Primarily metabolized by CYP3A4; also minor contribution from CYP2C9, CYP2C19, and CYP2D6.
Olopatadine undergoes minimal hepatic metabolism; approximately 60-70% excreted unchanged in urine. Metabolites include N-demethylated and N-oxide derivatives; CYP450 enzymes not significantly involved.
Approximately 90% of the dose is eliminated in feces, with less than 10% recovered in urine. Renal excretion accounts for about 9% of total clearance, primarily as unchanged drug. Biliary/fecal elimination is the major route.
Primarily renal excretion: approximately 60% of dose excreted unchanged in urine; fecal elimination accounts for less than 10%.
Approximately 85% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 70-80% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 1.4 L/kg (range 1.0-2.0 L/kg), indicating extensive distribution into tissues beyond total body water.
Volume of distribution is approximately 1.4 L/kg, indicating distribution into total body water.
Oral bioavailability is approximately 50% (range 30-70% due to first-pass metabolism) for the tablet formulation. Absolute bioavailability is moderate due to presystemic clearance.
Ocular bioavailability is low due to nasolacrimal drainage and systemic absorption; systemic bioavailability from ocular dose is less than 5%.
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal impairment (Cr Cl <10 m L/min).
No dosage adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution as safety has not been established.
Contraindicated in severe hepatic impairment (Child-Pugh C); no adjustment for mild to moderate impairment.
No dosage adjustment required for mild to moderate hepatic impairment. For severe hepatic impairment (Child-Pugh class C), use with caution as safety has not been established.
Not established; safety and efficacy in patients <18 years not studied.
For children 2 years of age and older: 1 drop in each affected eye once daily. Safety and efficacy in children under 2 years have not been established.
Use with caution due to potential decreased hepatic/renal function; consider lower starting dose (20 mg).
No specific dosage adjustment required. Use the same dose as for younger adults. Overall, no differences in safety or efficacy were observed between elderly and younger patients.
No FDA boxed warning.
None.
Coronary artery vasospasm and ischemic heart disease,Cerebrovascular events (stroke, transient ischemic attack),Life-threatening serotonin syndrome (especially with SSRIs/SNRIs),Hypertensive crisis in patients with uncontrolled hypertension,Risk of myocardial ischemia in patients with risk factors
Not for injection; for topical ophthalmic use only.,Do not wear contact lenses if eyes are red; wait at least 10 minutes after instillation before inserting lenses.,Contains benzalkonium chloride which may be absorbed by soft contact lenses.,May cause transient stinging or burning upon instillation.
History of ischemic heart disease or coronary artery vasospasm,Uncontrolled hypertension,Hemiplegic or basilar migraine,Use within 24 hours of another triptan or ergotamine,Concurrent use of MAO inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment (Child-Pugh C)
Hypersensitivity to olopatadine or any component of the formulation.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4, increasing eletriptan exposure and risk of adverse effects. No other significant food interactions reported.
No known food interactions. No dietary restrictions required.
Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. Avoid in third trimester due to possible uterine atony or decreased placental perfusion.
Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic doses. No adequate human studies exist. Risk cannot be ruled out; use only if benefit outweighs potential fetal risk.
Excreted into breast milk in low amounts (M/P ratio unknown). Relative infant dose estimated at <1% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for irritability and sleep disturbance.
Olopatadine is excreted in rat milk at concentrations ~2.4 times higher than maternal plasma. No human data on M/P ratio. Caution advised; consider risk-benefit and monitor infant for anticholinergic effects.
No specific dose adjustment recommended; pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may reduce efficacy, but standard dosing remains safe. Consider lowest effective dose.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended based on available data. Use at lowest effective dose and shortest duration.
Eletriptan has higher lipophilicity and longer half-life than sumatriptan, potentially offering better CNS penetration and sustained efficacy. Contraindicated within 24 hours of other triptans or ergotamines. Avoid in patients with severe hepatic impairment (Child-Pugh C) as metabolism is CYP3A4-dependent. Maximum single dose 40 mg; may repeat after 2 hours if no response, but do not exceed 80 mg/day. Onset typically within 30 minutes; if first dose fails, consider alternative therapy for subsequent attacks.
Pataday Once Daily Relief contains olopatadine 0.2%, a mast cell stabilizer and antihistamine. For optimal efficacy, instruct patients to administer one drop in each affected eye once daily. Shake bottle before use. Wait at least 5 minutes before inserting contact lenses due to preservative (benzalkonium chloride). Monitor for transient burning or stinging upon instillation. Not for injection. Patients using additional ophthalmic products should separate by 5 minutes.
Take at the first sign of migraine headache, not for prevention.,Do not take more than 80 mg in 24 hours; wait at least 2 hours between doses.,Avoid taking within 24 hours of other triptans or ergotamine medications.,Report chest pain, palpitations, or shortness of breath immediately.,Do not use if you have uncontrolled high blood pressure, coronary artery disease, or history of stroke.,Grapefruit juice may increase drug levels; avoid consumption during treatment.,Swallow tablet whole; do not crush or chew.
Do not touch dropper tip to any surface to avoid contamination.,Remove contact lenses before use; wait 10 minutes before reinserting.,May cause temporary blurred vision; avoid driving until vision clears.,If you miss a dose, use it as soon as remembered, but skip if near next dose.,Keep bottle tightly closed when not in use; store at room temperature.
"Eletriptan, a 5-HT1B/1D receptor agonist used for migraine, and ondansetron, a 5-HT3 receptor antagonist antiemetic, both increase serotonergic activity via different mechanisms. Concurrent use may lead to excessive serotonin accumulation, potentially triggering serotonin syndrome, characterized by neuromuscular excitation, autonomic instability, and altered mental status. While the interaction is mechanistically plausible, clinical reports are rare, and caution is advised particularly in patients on multiple serotonergic agents."
"Concomitant use of eletriptan, a 5-HT1B/1D receptor agonist, with maprotiline, a tetracyclic antidepressant that inhibits serotonin reuptake, may result in additive serotonergic effects. This increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. Patients combining these agents require close monitoring for symptoms such as hyperthermia, clonus, hyperreflexia, and agitation."
"Concomitant use of eletriptan and almotriptan, both triptan-class 5-HT1B/1D receptor agonists, increases the risk of serotonin syndrome and additive vasoconstriction, including coronary vasospasm. Excessive serotonergic activity may lead to neuromuscular excitation, autonomic instability, and altered mental status, while additive arterial vasoconstriction can precipitate severe hypertension or ischemic events, especially in patients with cardiovascular risk factors."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELETRIPTAN HYDROBROMIDE vs PATADAY ONCE DAILY RELIEF, answered by our medical review team.
ELETRIPTAN HYDROBROMIDE is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibition of trigeminal nerve transmission.. PATADAY ONCE DAILY RELIEF is a Ophthalmic Antiallergic Agent that works by Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELETRIPTAN HYDROBROMIDE and PATADAY ONCE DAILY RELIEF depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELETRIPTAN HYDROBROMIDE is: 40 mg orally once, may repeat after 2 hours if headache recurs; maximum 80 mg/day.. The standard adult dose of PATADAY ONCE DAILY RELIEF is: 1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELETRIPTAN HYDROBROMIDE and PATADAY ONCE DAILY RELIEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELETRIPTAN HYDROBROMIDE is classified as Category D/X. Limited human data; animal studies show no teratogenicity at clinically relevant doses. First trimester: risk cannot be excluded; second/third trimester: no known increased risk. A. PATADAY ONCE DAILY RELIEF is classified as Category C. Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.